- Two new Panel members
- Now 15 members on Panel
- Exchange will continue to look to add Panel members as appropriate
The Stock Exchange of Hong Kong Limited (the Exchange), a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited (HKEX), today (Tuesday) announced that it has added two members to its Biotech Advisory Panel (the Panel).
As stated in the news releaseon the formation of the Panel, the Exchange will look to include additional members as appropriate. The Exchange has since appointed two additional members, Song Ruilin and Lawrence Tian, to the Panel to further enhance its pool of expertise.
The biographies of the two additional members are set out in the Appendix.
The Panel was formed to assist the Exchange in its review of listing applications from biotech firms applying for listing under the new Biotech chapter of its Listing Rules. The role of the members of the Panel is advisory only and they will be consulted by the Exchange on an individual and “as needed” basis. A brief description of the function of the Panel together with a list of its 15 members is available on the HKEX website.
The Exchange will continue to look to include additional members on the Panel as appropriate.
APPENDIX – BIOGRAPHIES OF NEW BIOTECH ADVISORY PANEL MEMBERS
SONG Ruilin
During the time he worked in the Legislative Affairs Office at the State Council of China, Mr Song Ruilin was mainly engaged in the legislative review and research of health and medicine for 22 years. He participated in China’s health and drug legislation activities from 1987 to 2006, in charge of the drafting and review of the current Drug Administration Law of the PRC, Law of the PRC on the Prevention and Treatment of Communicable Diseases, Law of the PRC on Medical Practitioners, Regulations on Medical Institutions, and Regulations for the Supervision and Administration of Medical Devices, etc.
Since 2007, Mr Song has been dedicated to the research of China’s pharmaceutical policies, especially the policies for pharmaceutical innovation. Under his leadership, Research Center for Medicinal Policy of Chinese Pharmaceutical Association and PhIRDA had finalised dozens of pharmaceutical policy projects in China and research on the reform of the China Healthcare, Drug Administration and Medical Insurance Reimbursement System, which was commissioned by the National Health and Family Planning Commission (NHFPC), China Food and Drug Administration (CFDA) and Ministry of Human Resources and Social Security of the People's Republic of China (MOHRSS).
Mr Song has been working as Executive President of PhIRDA (former named China Pharmaceutical Industry Research and Development Association) since 2009. With the great support of governments and industry, Mr Song changed the original management model of the non-profit organisation, centring on the principles of “Innovation, Industrialisation, Internationalisation”, managing with an innovative spirit and mechanism. After years of hard work, Mr Song has made PhIRDA into an integrated and innovative platform for cooperation among pharmaceutical innovation enterprises, R&D institutions, clinical trial and investment institutions. Today, PhIRDA has become the most influential organisation in the field of pharmaceutical innovation in China.
Mr Song also works as Director of Chinese Pharmaceutical Association (CPA), Standing Director of Chinese Pharmacist Association, Arbitrator of China International Economic and Trade Arbitration Commission (CIETAC), Expert of Capital Medical Reform Expert Group among other important social positions. Mr Song obtained a Bachelor of Laws degree from China University of Political Science and Law in 1985 and a Master in Business Administration degree from China Europe International Business School in 2004.
TIAN Lawrence
Dr Lawrence Tian is a Founding Partner of YuanMing Capital. YuanMing Capital focuses on investments in pharmaceutial research and development, innovative medical devices and high-end medical services in both China and the US. YuanMing has successfully invested in a dozen leading biopharma companies, including BeiGene, Ascentage Pharma, Mevion Medical Systems, Pharmacodia, CF PharmTech, JW Therapeutics and Digital China Health.
Prior to founding YuanMing Capital, Dr Tian established China International Futures Corporation, and co-founded Wumart Stores, Inc. and Yabuli Ski Resort. He also served as Chairman of China Chengtong Group. Since 2010, Dr Tian has been committed to promoting China’s capital investment in US life science innovative companies, and has accumulated solid experience and an outstanding track record.
Dr Tian is the Founder and Chairman of China Entrepreneurs Forum and China-US Business Leaders Roundtable. As a core organiser of various high-end meetings for entrepreneurs of both countries, Dr Tian is an influential figure in the US-China business scene and has extensive social influence. He is also the Chairman of Investment Committee of China Pharmaceutical Industry Research and Development Association. Dr Tian obtained his Master’s and Doctoral degrees from Wuhan University, and he was the recipient of China’s highest prize for economics: The China Economics Theory Innovation Award.
Ends